Fatty acids and lipid mediators in inflammatory bowel disease: from mechanism to treatment
Frontiers in Immunology · 05.10.2023 · 14
DOI: 10.3389/fimmu.2023.1286667 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Immunology, online erschienen am 05.10.2023. Verfasst von Dong Yan und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, The Third Xiangya Hospital of Central South University, Changsha, China. Hauptthemen laut MEDLINE: Inflammatory Bowel Diseases, Fatty Acids, Omega-3. Die Arbeit wurde bisher 132-mal zitiert (Crossref) und nennt 248 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Inflammatory Bowel Disease (IBD) is a chronic, relapsing inflammatory disorder of the gastrointestinal tract. Though the pathogenesis of IBD remains unclear, diet is increasingly recognized as a pivotal factor influencing its onset and progression. Fatty acids, essential components of dietary lipids, play diverse roles in IBD, ranging from anti-inflammatory and immune-regulatory functions to gut-microbiota modulation and barrier maintenance. Short-chain fatty acids (SCFAs), products of indigestible dietary fiber fermentation by gut microbiota, have strong anti-inflammatory properties and are seen as key protective factors against IBD. Among long-chain fatty acids, saturated fatty acids, trans fatty acids, and ω-6 polyunsaturated fatty acids exhibit pro-inflammatory effects, while oleic acid and ω-3 polyunsaturated fatty acids display anti-inflammatory actions. Lipid mediators derived from polyunsaturated fatty acids serve as bioactive molecules, influencing immune cell functions and offering both pro-inflammatory and anti-inflammatory benefits. Recent research has also highlighted the potential of medium- and very long-chain fatty acids in modulating inflammation, mucosal barriers, and gut microbiota in IBD. Given these insights, dietary intervention and supplementation with short-chain fatty acids are emerging as potential therapeutic strategies for IBD. This review elucidates the impact of various fatty acids and lipid mediators on IBD and delves into potential therapeutic avenues stemming from these compounds.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, The Third Xiangya Hospital of Central South University, Changsha, China.
- Hunan Key Laboratory of Non-Resolving Inflammation and Cancer, Cancer Research Institute, Central South University, Changsha, China.
Zitieren
APA
Yan, D., Ye, S., He, Y., Wang, S., Xiao, Y., Xiang, X., Deng, M., Luo, W., Chen, X., & Wang, X. (2023). Fatty acids and lipid mediators in inflammatory bowel disease: from mechanism to treatment. Frontiers in Immunology, 14. https://doi.org/10.3389/fimmu.2023.1286667
Vancouver
Yan D, Ye S, He Y, Wang S, Xiao Y, Xiang X, et al. Fatty acids and lipid mediators in inflammatory bowel disease: from mechanism to treatment. Frontiers in Immunology. 2023;14. doi:10.3389/fimmu.2023.1286667
BibTeX
@article{Yan2023,
author = {Yan, Dong and Ye, Shuyu and He, Yue and Wang, Sidan and Xiao, Yi and Xiang, Xin and Deng, Minzi and Luo, Weiwei and Chen, Xuejie and Wang, Xiaoyan},
title = {Fatty acids and lipid mediators in inflammatory bowel disease: from mechanism to treatment},
journal = {Frontiers in Immunology},
year = {2023},
volume = {14},
doi = {10.3389/fimmu.2023.1286667}
}
EUVIMED